Periorbital Dermatitis from EGFR Tyrosine Kinase Inhibitor

Abstract

A 56-year-old woman with EGFR mutation metastatic adenocarcinoma presented with bilateral eyelid inflammation, itching and persistent tearing for 2 months. She had been taking erlotinib 150 mg/day 10 months for lung cancer. She also had pruritic facial rash on both eyebrow area. She was initially diagnosed periorbital dermatitis induced by erlotinib and the drug was discontinued with supportive treatment. After one month, she had complete resolution of eye and skin problem. This was uncommon but quite newly recognized adverse events of erlotinib. The differential diagnosis includes allergic conjunctivitis and infection. Physicians in charge should ask for history of regular medicine and having thorough physical examination of other systems in order to make early diagnosis and management.